Cargando…

Study of the clinicopathological features of soluble PD-L1 in lung cancer patients

Objective: In recent years, an association between serum soluble immune checkpoint molecules (sICMs) and malignant tumors has been reported, which may become important biomarkers in the future. Although several reports have suggested a correlation between sICMs and prognosis, their origin is unclear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Takanobu, Nonomura, Ryo, Tabata, Toshiharu, Yoshimura, Naruo, Hata, Shuko, Shimada, Hiroki, Nakamura, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Association of Rural Medicine 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832313/ https://www.ncbi.nlm.nih.gov/pubmed/36700127 http://dx.doi.org/10.2185/jrm.2022-040

Ejemplares similares

For which lung cancer patients is re-administration of immune checkpoint inhibitors effective?
por: Sasaki, Takanobu, et al.
Publicado: (2021)

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
por: Ishibashi, Naoya, et al.
Publicado: (2023)

Prediction of Postoperative Respiratory Complications after Lobectomy in Lung Cancer Patients with COPD by Quantitative Image Analysis: A Historical Cohort Study
por: Nonomura, Ryo, et al.
Publicado: (2022)

PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells
por: Inoue, Chihiro, et al.
Publicado: (2019)

A Solitary Necrotizing Sarcoid Granulomatosis-like Pulmonary Lesion Possibly Associated with Propionibacterium acnes and Mycobacterium avium
por: Murakami, Keigo, et al.
Publicado: (2021)

Clinicopathological Significance of Estrogen Receptor β and Estrogen Synthesizing/Metabolizing Enzymes in Urothelial Carcinoma of Urinary Bladder
por: Sato, Naomi, et al.
Publicado: (2021)

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
por: Bai, Yanhua, et al.
Publicado: (2017)

PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
por: Lee, Sze‐Hwei, et al.
Publicado: (2021)

Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer
por: Imai, Yushi, et al.
Publicado: (2020)

Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer
por: Li, Yue, et al.
Publicado: (2022)

Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors
por: Chen, Yanmei, et al.
Publicado: (2018)

Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features
por: Watari, Jiro, et al.
Publicado: (2019)

PD‐L1 expression on tumor or stromal cells of nodal cytotoxic T‐cell lymphoma: A clinicopathological study of 50 cases
por: Yamashita, Daisuke, et al.
Publicado: (2020)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Kumar, Utpal, et al.
Publicado: (2021)

YM750, an ACAT Inhibitor, Acts on Adrenocortical Cells to Inhibit Aldosterone Secretion Due to Depolarization
por: Shimada, Hiroki, et al.
Publicado: (2022)

Clinicopathological analysis of PD-L2 expression in colorectal cancer
por: Guo, Peng-Da, et al.
Publicado: (2018)

Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation
por: Kaiho, Taisuke, et al.
Publicado: (2023)

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
por: Zhu, Xinxin, et al.
Publicado: (2017)

Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer
por: Chüeh, Anderly C., et al.
Publicado: (2017)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma
por: Miyake, Makito, et al.
Publicado: (2020)

FGFR2 gene amplification and clinicopathological features in gastric cancer
por: Matsumoto, K, et al.
Publicado: (2012)

Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer
por: Wang, Yu, et al.
Publicado: (2016)

Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures
por: Lin, Ziying, et al.
Publicado: (2016)

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications
por: Xing, Wei, et al.
Publicado: (2016)

PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2022)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
por: Krueger, Kimberly, et al.
Publicado: (2022)

Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
por: Wu, Hong, et al.
Publicado: (2021)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Clinicopathological features of intraductal papillary mucinous neoplasm derived from ectopic pancreas: A systematic review
por: Kimura, Jiro, et al.
Publicado: (2022)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
por: Krueger, Kimberly, et al.
Publicado: (2022)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer
por: Inoue, Yusuke, et al.
Publicado: (2016)

Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells
por: Ishikawa, Eri, et al.
Publicado: (2018)

Elevated Plasma Soluble PD-L1 Levels in Out-of-Hospital Cardiac Arrest Patients
por: Sumiyoshi, Miho, et al.
Publicado: (2021)

Abnormal Expression of Serum Soluble E-Cadherin is Correlated with Clinicopathological Features and Prognosis of Breast Cancer
por: Liang, Zhi, et al.
Publicado: (2014)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors
por: Cha, Yoon Jin, et al.
Publicado: (2017)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o0qvgsjbahc358u4iejqpcq1rl